Treating or preventing nephrogenic diabetes insipidus
In certain embodiments, the disclosure relates to methods of treating or preventing nephrogenic diabetes insipidus comprising administering an effective amount of a AMPK activator to a subject in need thereof, wherein In certain embodiments, the AMPK activator is metformin or salt thereof. In certain embodiments, the subject has been diagnosed with nephrogenic diabetes insipidus.
1. A method of treating nephrogenic diabetes insipidus comprising administering an effective amount of an AMPK activator to a subject in need thereof wherein the subject has symptoms of excessive urination and excessive thirst wherein urine of the subject does not contain glucose.
2. The method of claim 1 , wherein the AMPK activator is metformin or salt thereof.
3. The method of claim 1 , wherein the subject has been diagnosed with nephrogenic diabetes insipidus.
4. The method of claim 1 , wherein the subject is restricted from drinking water and an hourly increase in osmolality of urine of the subject is less than 30 mOsm/kg per hour for at least 3 hours.
5. The method of claim 1 , wherein the subject is not responsive to vasopressin.
6. The method of claim 1 , wherein the AMPK activator is administered in combination with a thiazide, indomethacin, amiloride, or other diuretic.
7. The method of claim 1 , wherein the AMPK activator is administered in combination with lithium.
8. The method of claim 1 , wherein the AMPK activator is cryptotanshinone.
9. The method of claim 1 , wherein the AMPK activator is 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside, A-769662 [4-hydroxy-3-(2′-hydroxy-[1,1′-biphenyl]-4-yl)-6-oxo-6,7-dihydrothieno[2,3-b]pyridine-5-carbonitrile], D942 [5-(3-(4-(2-(4-Fluorophenyl) ethoxy)phenyl)propyl)furan-2-carboxylic acid], WS070117 [O2′,O3′,O5′-tri-acetyl-N6-(3-hydroxylaniline)adenosine], PT1 [2-Chloro-5-[[5-[[5-(4,5-Dimethyl-2-nitrophenyl)-2-furanyl]methylene]-4,5-dihydro-4-ox-o-2-thiazolyl]amino]benzoic acid] or salts thereof.